Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response
Protein arginine methyltransferases (PRMTs) regulate diverse biological processes and are increasingly being recognized for their potential as drug targets. Here we report the discovery of a potent, selective, and cell-active chemical probe for PRMT7. SGC3027 is a cell permeable prodrug, which in ce...
Saved in:
Published in | Nature communications Vol. 11; no. 1; pp. 2396 - 15 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
14.05.2020
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Protein arginine methyltransferases (PRMTs) regulate diverse biological processes and are increasingly being recognized for their potential as drug targets. Here we report the discovery of a potent, selective, and cell-active chemical probe for PRMT7. SGC3027 is a cell permeable prodrug, which in cells is converted to SGC8158, a potent, SAM-competitive PRMT7 inhibitor. Inhibition or knockout of cellular PRMT7 results in drastically reduced levels of arginine monomethylated HSP70 family stress-associated proteins. Structural and biochemical analyses reveal that PRMT7-driven in vitro methylation of HSP70 at R469 requires an ATP-bound, open conformation of HSP70. In cells, SGC3027 inhibits methylation of both constitutive and inducible forms of HSP70, and leads to decreased tolerance for perturbations of proteostasis including heat shock and proteasome inhibitors. These results demonstrate a role for PRMT7 and arginine methylation in stress response.
Protein arginine methyltransferases (PRMTs) are increasingly recognized as potential therapeutic targets but PRMT7 remains an understudied member of this enzyme family. Here, the authors develop a chemical probe for PRMT7 and apply it to elucidate the role of PRMT7 in the cellular stress response. |
---|---|
Bibliography: | S10OD021527; AC02-06CH11357; 115766 USDOE Office of Science (SC) Innovative Medicines Initiative Natural Sciences and Engineering Research Council of Canada (NSERC) Canadian Institutes of Health Research (CIHR) Bayer Pharma AG Janssen, Merck KGaA Takeda Stand Up to Cancer Canada National Institutes of Health (NIH) American Association for Cancer Research International – Canada Pfizer Eshelman Institute for Innovation AbbVie Ontario Ministry of Research, Innovation and Science (MRIS) Novartis Pharma AG São Paulo Research Foundation (FAPESP) Wellcome Government of Ontario Boehringer Ingelheim Canada Foundation for Innovation (CFI) Genome Canada National Institute of General Medical Sciences (NIGMS) MSD |
ISSN: | 2041-1723 2041-1723 |
DOI: | 10.1038/s41467-020-16271-z |